Adrenaline induced inflammation inflammation of the whole body caused by the stress hormone adrenaline
Conditions
Interventions
Participants will receive a continuous adrenaline infusion at a continuous rate
of 0.04 µg/kg/min for 60 minutes. The infusion will start after a 30 minute
equilibration period follow insertion of t
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Ability to provide written informed consent Body-Mass Index: 19-30 kg/m2 Age >=16 years,
Exclusion criteria
Exclusion criteria: Any event of cardiovascular disease in the past 5 years (e.g. myocardial infarction, stroke, heart failure, symptomatic peripheral arterial disease) Pregnancy or breastfeeding or unwillingness to undertake birth control measures Epilepsy, Current treatment with Alpha or beta blockers ( doxazosin, propranolol) History of panic disorders History of Arrhythmias Use of immune-modifying drugs or antibiotics Use of tricyclic antidepressants or MAO inhibitors Use of statins (e.g. stop statins >2 weeks before performing blood sampling. Any infection with systemic symptoms in past 2 weeks Vaccination in the past 2 weeks Proliferative retinopathy Nephropathy with an estimated glomerular filtration rate (by MDRD) *60ml/min/1.73m2 Overt impaired hypoglycaemic awareness assed by the Clarke Questionnaire 4 or highe
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of monocytes following 60 minutes of adrenaline infusion compared to baseline to asses the adrenaline effect on the inflammatory response. . | — |
Secondary
| Measure | Time frame |
|---|---|
| * Leukocyte count at the time points 30 minutes, 60 minutes, +1 day, +3 days and 1 week after start infusion. * Leukocyte phenotype using flow cytometry ( e.g. Granulocytes, NK-cells) * Ex vivo production of pro- and anti-inflammatory cytokines and chemokines after ex vivo stimulation of isolated monocytes, including TNF-a, IL-6, IL-10 and IL-1β. * Distribution of pro- and anti-inflammatory monocyte subsets using FACS (Fluorescence-activated Cell Sorting) * Pro-inflammatory proteins using Olink Proteomics AB inflammation panel with 92 circulating inflammatory proteins (29) ( e.g. EN-rage, FIT3L) * Inflammatory plasma protein using ELISA, ( e.g high sensitive-crp) * Atherogenic parameters using ELISA method including but not limited to, VCAM-1, ICAM-1, E-Selectin, P-selectin, PAI-1, Plasma Endothelin * Plasma levels of hormones ( Cortisol, insulin, glucagon, growth-hormone, adrenaline, noradrenaline) * Glucose variability measured by the blinded continuous glucose monitor including but not limited to, measuring time within range, amount of hypoglycaemic events, amount of hyperglycaemic events. Other study parameters - HbA1c - Creatinine - Vitals ( blood pressure and heart rate) - BMI - Age - Sex - Duration of diabetes ( years) - Hypoglycaemia awareness using the Clarke questionnaire owth-hormone) | — |
Countries
Netherlands
Outcome results
None listed